Johnson & Johnson (Johnson & Johnson) Accounts Payable & Accrued Expense

: $38,838 Mil (As of Dec. 2023)

View and export this data going back to 1944. Start your Free Trial

Johnson & Johnson's quarterly accounts payable & accrued expense declined from Jun. 2023 ($39,407 Mil) to Sep. 2023 ($37,163 Mil) but then increased from Sep. 2023 ($37,163 Mil) to Dec. 2023 ($38,838 Mil).

Johnson & Johnson's annual accounts payable & accrued expense declined from Dec. 2021 ($37,874 Mil) to Dec. 2022 ($36,407 Mil) but then increased from Dec. 2022 ($36,407 Mil) to Dec. 2023 ($38,838 Mil).

Johnson & Johnson Accounts Payable & Accrued Expense Historical Data

The historical data trend for Johnson & Johnson's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

31,408.00

36,378.00

37,874.00

36,407.00

38,838.00

Johnson & Johnson Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense																40,163.00	39,407.00	37,163.00	38,838.00	-

Johnson & Johnson Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Johnson & Johnson (Johnson & Johnson) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (NYSE:JNJ) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

JNJ:Peru JNJ:Mexico JNJ_KZ:Kazakhstan 1JNJ:Italy JNJd:UK 0R34:UK JNJ0:Germany JNJ:Germany JNJ:Germany JNJ:Germany JNJ:Germany JNJ:Canada JNJB34:Brazil JNJ:Austria JNJ:Argentina

Address

One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933

Website

https://www.jnj.com

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.

Executives

Timothy Schmid	officer: EVP, WW Chair, MedTech	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
William Hait	officer: See Remarks	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Peter Fasolo	officer: VP, Worldwide Human Resources	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Kathryn E Wengel	officer: EVP, Chief GSC Officer	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
John C Reed	officer: EVP, Pharmaceuticals R&D	ONE JOHNSON & JOHNSON PLAZA, WHQ 2134, NEW BRUNSWICK NJ 08933
James D. Swanson	officer: EVP, Chief Information Officer	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Paula A Johnson	director	22 CHERRY HILL DRIVE, DANVERS MA 01923
Joseph J Wolk	officer: Exec VP, CFO	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Ashley Mcevoy	officer: EVP, WW Chair, Medical Devices	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Jennifer L Taubert	officer: EVP, WW Chair, Pharmaceuticals	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Robert J Decker	officer: Controller, CAO	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Thibaut Mongon	officer: Exec VP, WW Chair, Consumer	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Elizabeth Forminard	officer: Executive VP, General Counsel	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Darius Adamczyk	director	855 S. MINT STREET, CHARLOTTE NC 28202
Vanessa Broadhurst	officer: EVP, Global Corp Aff.	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933